Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/2010
11/25/2010WO2010134086A1 Medicinal formulation containing selected cytokines
11/25/2010WO2010133834A2 Peptide
11/25/2010WO2010133828A1 Bifunctional polypeptides
11/25/2010WO2010133663A1 Serotonin 5-ht3 receptor antagonists for use in the treatment of lesional vestibular disorders
11/25/2010WO2010133662A1 Use of il-17 polypeptides for use in the prevention or treatment of atherosclerosis
11/25/2010WO2010133374A2 Therapeutic composition comprising microspheres
11/25/2010WO2010133306A1 Process for the preparation of ibodutant (men15596) and related intermediates
11/25/2010WO2010133298A1 Control of uric acid homeostasis
11/25/2010WO2010133071A1 Highly purified follicle stimulating hormone from urea and method for preparing thereof
11/25/2010WO2010133000A1 Selective caspase inhibitors and uses thereof
11/25/2010WO2010132954A1 Method of treating periodontal disease by administering antagonists of par-2
11/25/2010WO2010114628A9 Formulation for inducing broadly reactive neutralizing anti-hiv antibodies
11/25/2010WO2010113177A3 Oral insulin delivery systems for controlling diabetes
11/25/2010WO2010112713A3 Proteasome-activating lightening peptides and compositions containing same
11/25/2010WO2010112712A3 Novel proteasome-activating anti-aging peptides and compositions containing same
11/25/2010WO2010112711A3 Novel proteasome-activating lightening peptides and compositions containing same
11/25/2010WO2010112710A3 Proteasome-activating anti-aging peptides and compositions containing same
11/25/2010WO2010107991A3 Use of ixolaris, a tissue factor inhibitor, for the treatment and prevention of cancer
11/25/2010WO2010103475A3 Use of serine protease inhibitors in the treatment of neutropenia
11/25/2010WO2010103292A3 A genotyping tool for improving the prognostic and clinical management of ms patients
11/25/2010WO2010092485A3 Combined treatment of multiple sclerosis
11/25/2010WO2010091679A3 Use of notch regulators for modulating the immune response by induction/suppression of interleukin-22
11/25/2010WO2010088899A3 Pharmaceutical composition containing l-ribozyme for treating adverse reactions by administering spiegelmers
11/25/2010WO2010083225A3 Targeted cryptosporidium biocides
11/25/2010WO2010081800A3 Hylauronic acid containing compositions for treatment of wounds, scars, post-surgical adhesion formation
11/25/2010WO2010079511A3 Mammalian colostrum derived nanopeptides for broadspectrum viral and recurrent infections with a method of isolation thereof
11/25/2010WO2009148580A3 Controlled release copolymer formulation with improved release kinetics
11/25/2010WO2009142842A9 Novel macrocyclic inhibitors of hepatitis c virus replication
11/25/2010WO2009137871A8 Methods of detecting cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells
11/25/2010WO2009135190A3 Therapeutic calcium phosphate particles and methods of making and using same
11/25/2010WO2009131548A8 Multimeric forms of antimicrobial peptides
11/25/2010US20100299769 Novel peptide involved in energy homeostasis
11/25/2010US20100299767 Trem-2 gene and protein as inhibitors of expression of ga733-2, and transgenic animals comprising the same and uses thereof
11/25/2010US20100298628 Stress urinary incontinence treatment
11/25/2010US20100298546 Dnas encoding tnf receptor family members
11/25/2010US20100298544 Cdr-grafted anti-tissue factor antibodies and methods of use thereof
11/25/2010US20100298528 Cystine knot molecules
11/25/2010US20100298242 Masking the taste of compositons containing salt
11/25/2010US20100298241 Pmma binding peptides
11/25/2010US20100298240 Pmma binding peptides
11/25/2010US20100298239 Peptide with multiple epitopes
11/25/2010US20100298238 Nontoxic shiga-like toxin mutant compositions and methods
11/25/2010US20100298237 Use of hdac inhibitors for treatment of cardiac rhythm disorders
11/25/2010US20100298236 Soluble gp130 muteins with improved binding activity
11/25/2010US20100298235 Epithelial cell growth promoter
11/25/2010US20100298234 Cancer therapeutic agents comprising a ligand for the neuromedin u receptor 2 (fm4) molecule as an active ingredient
11/25/2010US20100298233 Compositions and methods related to profiling a plurality of cells based on peptide binding
11/25/2010US20100298232 Peptides targeting TNF family receptors and antagonizing TNF action, compositions, methods and uses thereof
11/25/2010US20100298231 Pmma binding peptides
11/25/2010US20100298230 Use of truncated cysteine il28 and il29 mutants to treat cancers and autoimmune disorders
11/25/2010US20100298229 Osteoprotegerin
11/25/2010US20100298228 Bone-reinforcing food material
11/25/2010US20100298227 Treatment of autoimmune conditions with Copolymer 1 and related copolymers
11/25/2010US20100298226 Polypeptides and polynucleotides encoding same and use thereof in the treatment of medical conditions associated with ischemia
11/25/2010US20100298225 Peptide gap junction modulators
11/25/2010US20100298224 Use of mutated antithrombins for treating or preventing coagulation disorders
11/25/2010US20100298223 Fibrinogen for treatment of bleeding in trauma and platelet disorders
11/25/2010US20100298222 Use of an agent that restores tissue perfusion and oxygenation
11/25/2010US20100298221 2-phenoxy nicotine acid derivative and use thereof
11/25/2010US20100298220 Fibroblast growth factor mutants having improved functional half-life and methods of their use
11/25/2010US20100298219 Method of treating cancer, neoplastic disorders, and symptoms thereof with compounds
11/25/2010US20100298218 Single Branch Heparin-Binding Growth Factor Analogs
11/25/2010US20100298217 Csf-1r mutants
11/25/2010US20100298216 Casein Derived Peptides And Uses Thereof in Therapy
11/25/2010US20100298215 Synthetic apolipoprotein e mimicking polypeptides and methods of use
11/25/2010US20100298214 Treatment of autoimmune disease
11/25/2010US20100298213 Pharmaceutically Active Insulin Receptor-Modulating Molecules
11/25/2010US20100298212 Modified Insulin Polypeptides and Their Uses
11/25/2010US20100298210 HCV NS3 Protease Inhibitors
11/25/2010US20100298209 Compounds for preventing or treating a viral infection
11/25/2010US20100298208 Biofilm prevention using lactoferrin
11/25/2010US20100298206 Hybrid oligomers, their preparation process and pharmaceutical compositions containing them
11/25/2010US20100298205 Methods and compositions for the treatment of conditions related to gastric acid secretion
11/25/2010US20100298203 Sdf-i-based glycosaminoglycan antagonists and methods of using same
11/25/2010US20100298202 Bri polypeptides and reducing ab aggregation
11/25/2010US20100298201 Peptidomimetic macrocycles with improved properties
11/25/2010US20100298200 Compounds and assays for controlling Wnt activity
11/25/2010US20100298168 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
11/25/2010US20100298164 Structure-based approach to design of inhibitors of protein-processivity factor interactions
11/25/2010US20100297732 Vectors with modified protease-dependent tropism
11/25/2010US20100297695 Nucleic Acids Encoding Chimeric CD154 Polypeptides
11/25/2010US20100297669 NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 191P4D12(b) USEFUL IN TREATMENT AND DETECTION OF CANCER
11/25/2010US20100297650 Nucleic acid and corresponding protein entitled 193p1e1b useful in treatment and detection of cancer
11/25/2010US20100297615 Egfr mutations
11/25/2010US20100297271 Compositions and methods for reducing hepatotoxicity associated with drug administration
11/25/2010US20100297267 Compositions for diabetes treatment and prophylaxis
11/25/2010US20100297262 Pharmaceutically active compositions comprising oxidative stress modulators (osm), new chemical entities, compositions and uses
11/25/2010US20100297258 Treatment of burns
11/25/2010US20100297255 Malleable implants containing demineralized bone matrix
11/25/2010US20100297253 Treatment of diabetes with milk protein hydrolysate
11/25/2010US20100297251 Encapsulated particles for enteric release
11/25/2010US20100297249 Enhancement of the efficacy of therapeutic proteins
11/25/2010US20100297247 Aqueous-Core Lipid Nanocapsules for Encapsulating Hydrophilic and/or Lipophilic Molecules
11/25/2010US20100297245 Methods and compositions for oral administration of protein and peptide therapeutic agents
11/25/2010US20100297238 Multifunctional and Biologically Active Matrices from Multicomponent Polymeric Solutions
11/25/2010US20100297222 Method for production of microcapsules using solid fat
11/25/2010US20100297219 Methods and Compositions for Modifying Apolipoprotein B mRNA Editing
11/25/2010US20100297218 Tissue adhesive compositions and methods thereof
11/25/2010US20100297213 Method For Making Patches By Electrospray
11/25/2010US20100297210 Repair and treatment of bone defect using agent produced by chondrocytes capable of hypertrophication and scaffold
1 ... 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 ... 3163